158 related articles for article (PubMed ID: 3488068)
41. [Adoptive immunotherapy in patients with malignant glioma].
Yoshida S; Takai N; Saito T; Tanaka R
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
[TBL] [Abstract][Full Text] [Related]
42. [Antimetastasis effect of lymphokine-activated killer (LAK) cells on fibrosarcoma in WKA rats].
Wang ZH; Li XB; Yao XD; Ba DN
Zhonghua Zhong Liu Za Zhi; 1986 Nov; 8(6):421-3. PubMed ID: 3495421
[TBL] [Abstract][Full Text] [Related]
43. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
44. Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
Beckner SK; Maluish AE; Longo DL
Cancer Res; 1987 Oct; 47(20):5504-8. PubMed ID: 3498534
[TBL] [Abstract][Full Text] [Related]
45. [Comparative study on cytotoxicity of lymphocytes from different tissues in laryngeal cancer].
An W
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):292-4, 314-5. PubMed ID: 8192933
[TBL] [Abstract][Full Text] [Related]
46. [Study on adoptive immunotherapy for experimental brain tumor].
Takai N
No To Shinkei; 1988 Jul; 40(7):689-95. PubMed ID: 3265631
[TBL] [Abstract][Full Text] [Related]
47. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
48. [Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report].
Nagane M; Oyama H; Shibui S; Nomura K
No To Shinkei; 1993 Jun; 45(6):547-51. PubMed ID: 8395864
[TBL] [Abstract][Full Text] [Related]
49. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
50. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Merchant RE; Grant AJ; Merchant LH; Young HF
Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
[TBL] [Abstract][Full Text] [Related]
51. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
[TBL] [Abstract][Full Text] [Related]
52. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
53. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
54. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
55. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
[TBL] [Abstract][Full Text] [Related]
57. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
58. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
59. [A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells].
Ueno Y; Kohgo Y; Sasagawa Y; Kanisawa Y; Nojiri S; Mahara K; Niitsu Y; Maekawa S; Oguma K; Urushizaki I
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2579-82. PubMed ID: 3497613
[TBL] [Abstract][Full Text] [Related]
60. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]